R. Gansevoort

Publications764
h-index86
Citations41,613
Highly Influential Citations1,434
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • S. Bakker
  • 551 Publications • 15,028 Citations
  • J. Coresh
  • 1,099 Publications • 132,456 Citations
  • P. D. de Jong
  • 399 Publications • 29,308 Citations
  • V. Torres
  • 438 Publications • 26,530 Citations
  • Publications
  • Influence
Genetic studies of body mass index yield new insights for obesity biology
TLDR
A genome-wide association study and Metabochip meta-analysis of body mass index (BMI), a measure commonly used to define obesity and assess adiposity, in up to 339,224 individuals provide strong support for a role of the central nervous system in obesity susceptibility. Expand
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.
TLDR
KDIGO has convened a workgroup to develop a global clinical practice guideline for the definition, classification, and prognosis of chronic kidney disease. Expand
Defining the role of common variation in the genomic and biological architecture of adult human height
TLDR
The results indicate a genetic architecture for human height that is characterized by a very large but finite number of causal variants, including mTOR, osteoglycin and binding of hyaluronic acid. Expand
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis
BACKGROUND Substantial controversy surrounds the use of estimated glomerular filtration rate (eGFR) and albuminuria to define chronic kidney disease and assign its stages. We undertook a… Expand
New genetic loci link adipose and insulin biology to body fat distribution
TLDR
A genome-wide association meta-analyses of traits related to waist and hip circumferences in up to 224,459 individuals implicated adipogenesis, angiogenesis, transcriptional regulation and insulin resistance as processes affecting fat distribution, providing insight into potential pathophysiological mechanisms. Expand
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
TLDR
Tolvaptan, as compared with placebo, slowed the increase in total kidney volume and the decline in kidney function over a 3-year period in patients with ADPKD but was associated with a higher discontinuation rate, owing to adverse events. Expand
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
TLDR
The epidemiology and pathophysiological mechanisms of cardiovascular risk in patients with chronic kidney disease are discussed, and methods of prevention are discussed. Expand
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic…
TLDR
The Global Burden of Disease, Injuries, and Risk Factor study 2013 is the first of a series of annual updates of the GBD and six new risk factors have been added: handwashing practices, occupational exposure to trichloroethylene, childhood wasting, childhood stunting, unsafe sex, and low glomerular filtration rate. Expand
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic…
TLDR
The challenge for governments and the health development community more broadly is to heed knowledge about the comparative effect of health risks, according to the World Health Organization. Expand
Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality.
TLDR
Declines in estimated GFR smaller than a doubling of serum creatinine concentration occurred more commonly and were strongly and consistently associated with the risk of ESRD and mortality, supporting consideration of lesser declines in Estimated GFR (such as a 30% reduction over 2 years) as an alternative end point for CKD progression. Expand
...
1
2
3
4
5
...